AMG 337 / ImmunityBio, Amgen 
Welcome,         Profile    Billing    Logout  
 13 Diseases   0 Trials   0 Trials   40 News 
  • ||||||||||  AMG 337 / ImmunityBio, Amgen
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Metastases:  QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma (clinicaltrials.gov) -  Nov 4, 2021   
    P2,  N=8, Active, not recruiting, 
    Active, not recruiting --> Terminated; Prematurely terminated due to lack of therapeutic effect Recruiting --> Active, not recruiting | N=37 --> 8 | Trial completion date: Jun 2021 --> Dec 2022 | Trial primary completion date: Mar 2021 --> Jun 2022
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Clinical, Journal:  Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature. (Pubmed Central) -  Jun 16, 2021   
    In vitro treatment of SCNPC patient-derived xenograft (PDX) cells with the MET inhibitor AMG-337 had no impact on cell viability in LuCaP 93 (MET+/RET+) and LuCaP 173.1 (MET-/RET-), whereas cabozantinib decreased cell viability of LuCaP 93, but not LuCaP 173.1...Our data suggest that the most likely mechanism of cabozantinib-mediated tumor growth suppression in SCNPC PDX models is through disruption of the tumor vasculature. Thus, cabozantinib may represent a potential therapy for patients with metastatic disease in tumor phenotypes that have a significant dependence on the tumor vasculature for survival and proliferation.
  • ||||||||||  AMG 337 / ImmunityBio, Amgen
    Enrollment change, Trial completion date, Trial primary completion date, Metastases:  QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma (clinicaltrials.gov) -  Mar 6, 2020   
    P2,  N=37, Recruiting, 
    Thus, cabozantinib may represent a potential therapy for patients with metastatic disease in tumor phenotypes that have a significant dependence on the tumor vasculature for survival and proliferation. N=10 --> 37 | Trial completion date: Dec 2020 --> Jun 2021 | Trial primary completion date: Oct 2020 --> Mar 2021
  • ||||||||||  AMG 337 / ImmunityBio, Amgen
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date, Metastases:  QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) -  Aug 28, 2019   
    P2,  N=0, Withdrawn, 
    N=10 --> 37 | Trial completion date: Dec 2020 --> Jun 2021 | Trial primary completion date: Oct 2020 --> Mar 2021 N=178 --> 0 | Trial completion date: Dec 2020 --> Aug 2019 | Recruiting --> Withdrawn | Trial primary completion date: Oct 2020 --> Aug 2019
  • ||||||||||  AMG 337 / NantWorks, Amgen
    Journal:  Clinical Implications and Translation of an Off-Target Pharmacology Profiling Hit: Adenosine Uptake Inhibition In Vitro. (Pubmed Central) -  Jul 23, 2019   
    When subjects were advised to drink coffee, an AR antagonist, prior to AMG 337, the severity of headaches was reduced, allowing them to continue treatment. These findings demonstrate the importance of carefully evaluating clinical observations during early drug development and the value of translational nonclinical studies to investigate the mechanism of action driving clinical observations.
  • ||||||||||  AMG 337 / ImmunityBio, Amgen
    Trial completion:  A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects (clinicaltrials.gov) -  Dec 20, 2018   
    P1/2,  N=11, Completed, 
    The promising response rate observed in patients with heavily pretreated MET-amplified tumors warrants further investigation.See related commentary by Ma, p. 2375. Active, not recruiting --> Completed
  • ||||||||||  AMG 337 / ImmunityBio, Amgen
    Trial completion date:  A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects (clinicaltrials.gov) -  Jul 5, 2018   
    P1/2,  N=11, Active, not recruiting, 
    Active, not recruiting --> Completed Trial completion date: Jun 2018 --> Sep 2018
  • ||||||||||  AMG 337 / ImmunityBio, Amgen
    Trial completion date, Trial primary completion date, Metastases:  QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) -  Jun 7, 2018   
    P2,  N=178, Recruiting, 
    Trial completion date: Jun 2018 --> Sep 2018 Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Oct 2019 --> Oct 2020
  • ||||||||||  AMG 337 / ImmunityBio, Amgen
    Trial completion date, Trial primary completion date, Metastases:  QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma (clinicaltrials.gov) -  Jun 7, 2018   
    P2,  N=10, Recruiting, 
    Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Oct 2019 --> Oct 2020 Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Oct 2019 --> Oct 2020
  • ||||||||||  AMG 337 / ImmunityBio, Amgen
    Enrollment open, Enrollment change, Trial initiation date, Metastases:  QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) -  Jan 5, 2018   
    P2,  N=178, Recruiting, 
    Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Oct 2019 --> Oct 2020 Not yet recruiting --> Recruiting | N=89 --> 178 | Initiation date: May 2017 --> Jan 2018
  • ||||||||||  AMG 337 / ImmunityBio, Amgen
    Enrollment open, Trial initiation date, Metastases:  QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma (clinicaltrials.gov) -  Jan 5, 2018   
    P2,  N=10, Recruiting, 
    Not yet recruiting --> Recruiting | N=89 --> 178 | Initiation date: May 2017 --> Jan 2018 Not yet recruiting --> Recruiting | Initiation date: May 2017 --> Jan 2018
  • ||||||||||  AMG 337 / ImmunityBio, Amgen
    Trial completion, Metastases:  A Study of AMG 337 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) -  Dec 23, 2016   
    P1,  N=111, Completed, 
    Phase classification: P1/2 --> P2 | N=308 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2016 --> Mar 2018 Active, not recruiting --> Completed
  • ||||||||||  AMG 337 / ImmunityBio, Amgen
    Trial termination, Trial primary completion date:  Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors (clinicaltrials.gov) -  Nov 10, 2016   
    P2,  N=60, Terminated, 
    Active, not recruiting --> Completed Active, not recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Oct 2016; Amgen decision following interim review of efficacy and safety data from the AMG 337 program.
  • ||||||||||  AMG 337 / ImmunityBio, Amgen
    Trial primary completion date:  Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors (clinicaltrials.gov) -  Jul 19, 2016   
    P2,  N=60, Active, not recruiting, 
    Active, not recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Oct 2016; Amgen decision following interim review of efficacy and safety data from the AMG 337 program. Trial primary completion date: Aug 2016 --> Jan 2017
  • ||||||||||  AMG 337 / ImmunityBio, Amgen
    Trial primary completion date:  A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects (clinicaltrials.gov) -  Mar 8, 2016   
    P1/2,  N=11, Active, not recruiting, 
    Trial primary completion date: Apr 2016 --> Aug 2016 Trial primary completion date: Apr 2016 --> Nov 2015
  • ||||||||||  AMG 337 / ImmunityBio, Amgen
    Trial primary completion date, Metastases:  A Study of AMG 337 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) -  Mar 7, 2016   
    P1,  N=111, Active, not recruiting, 
    Trial primary completion date: Apr 2016 --> Nov 2015 Trial primary completion date: Aug 2016 --> Oct 2015
  • ||||||||||  AMG 337 / ImmunityBio, Amgen
    Enrollment closed, Enrollment change, Metastases:  A Study of AMG 337 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) -  Oct 15, 2015   
    P1,  N=111, Active, not recruiting, 
    Trial primary completion date: Aug 2016 --> Oct 2015 Recruiting --> Active, not recruiting | N=149 --> 111
  • ||||||||||  AMG 337 / ImmunityBio, Amgen
    Enrollment closed, Enrollment change:  A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects (clinicaltrials.gov) -  May 19, 2015   
    P1/2,  N=11, Active, not recruiting, 
    Recruiting --> Active, not recruiting | N=140 --> 60 Recruiting --> Active, not recruiting | N=149 --> 11
  • ||||||||||  AMG 337 / ImmunityBio, Amgen
    Trial primary completion date, Metastases:  A Study of AMG 337 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) -  Jan 26, 2015   
    P1,  N=149, Recruiting, 
    Recruiting --> Active, not recruiting | N=149 --> 11 Trial primary completion date: Feb 2015 --> Aug 2016
  • ||||||||||  AMG 337 / ImmunityBio, Amgen
    Enrollment open:  A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects (clinicaltrials.gov) -  May 5, 2014   
    P1/2,  N=149, Recruiting, 
    Trial primary completion date: Feb 2015 --> Aug 2016 Not yet recruiting --> Recruiting